The endocannabinoid system in the physiology and pathology of the basal ganglia

Cannabinoids and the Brain

Volumn , Issue , 2008, Pages 423-483

  Gerdeman, Gregory L ^b   Fernández Ruiz, Javier ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b C/o John Schindler ^*

Author keywords

[No Author keywords available]

Indexed keywords

EID: 52949123460     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-74349-3_21     Document Type: Chapter

References (334)

1. Abeliovich A, Beal MF (2006) Parkinsonism genes: culprits and clues. J Neurochem 99:1062-1072.
2. Ade KK, Lovinger DM (2007) Anandamide regulates postnatal development of long-term synaptic plasticity in the rat dorsolateral striatum. J Neurosci 27:2403-2409.
3. Ade KK, Kunos G, Lovinger DM (2003) Stimulation of dopamine D2 receptors induces the formation of anandamide (AEA) but not 2-arachidonoyl glycerol (2-AG) in rat cortical-striatal slices. Symposium on the Cannabinoids International Cannabinoid Research Society (Burlington, VT), p. 88.
4. Aguado T, Monory K, Palazuelos J, Stella N, Cravatt B, Lutz B, Marsicano G, Kokaia Z, Guzman M, Galve-Roperh I (2005) The endocannabinoid system drives neural progenitor proliferation. FASEB J 19:1704-1706.
5. Aiken CT, Tobin AJ, Schweitzer ES (2004) A cell-based screen for drugs to treat Huntington's disease. Neurobiol Dis 16:546-555.
6. Alexi T, Hughes PE, Faull RLM, Williams LE (1998) 3-Nitropropionic acid's lethal triplet: cooperative pathways of neurodegeneration. Neuroreport 9:57-64.
7. Alger B (2002) Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids. Prog Neurobiol 68:247-286.
8. 2 agonist in rats with unilateral lesions of the nigrostriatal pathway. Brain Res 691:106-114.
9. 2 receptor in the rat cerebellum: An immunohistochemical study. Neurosci Lett 396:113-116.
10. Baker D, Pryce G (2003) The therapeutic potential of cannabis in multiple sclerosis. Expert Opin Investig Drugs 12:561-567.
11. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A, Khanolkar A, Layward L, Fezza F, Bisogno T, Di Marzo V (2001) Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 15:300-302.
12. Barnabe-Heider F, Miller FD (2003) Endogenously produced neurotrophins regulate survival and differentiation of cortical progenitors via distinct signaling pathways. J Neurosci 23:5149-5160.
13. 2 receptor responses by an anandamide transport inhibitor. J Neurosci 20:3401-3407.
14. 2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaqueassociated glia in Alzheimer's disease brains. J Neurosci 23:11136-11141.
15. Benito C, Kim WK, Chavarria I, Hillard CJ, Mackie K, Tolon RM, Williams K, Romero J (2005) A glial endogenous cannabinoid system is upregulated in the brains of macaques with simian immunodeficiency virus-induced encephalitis. J Neurosci 25:2530-2536.
16. 2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J Neurosci 27:2396-2402.
17. 2 receptors and endocannabinoids mediates the effects of cocaine on striatal GABAergic transmission. Neuropsychopharmacology 29:1488-1497.
18. 1 receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis. Synapse 41:195-202.
19. Bevan MD, Magill PJ, Terman D, Bolam JP, Wilson CJ (2002) Move to the rhythm: oscillations in the subthalamic nucleus-external globus pallidus network. Trends Neurosci 25:525-531.
20. Bisogno T, Berrendero F, Ambrosino G, Cebeira M, Ramos JA, Fernández-Ruiz JJ, Di Marzo V (1999) Brain regional distribution of endocannabinoids: Implications for their biosynthesis and biological function. Biochem Biophys Res Commun 256:377-380.
21. Bisogno T, Cascio MG, Saha B, Mahadevan A, Urbani P, Minassi A, Appendino G, Saturnino C, Martin B, Razdan R, Di Marzo V (2006) Development of the first potent and specific inhibitors of endocannabinoid biosynthesis. Biochim Biophys Acta 1761:205-212.
22. Bizat N, Hermel JMH, Humbert S, Jacquard C, Créminon C, Escartin C, Saudou F, Krajewski S, Hantraye P, Brouillet E (2003) In vivo calpain/caspase cross-talk during 3-nitropropionic acidinduced striatal degeneration: Implication of a calpain-mediated cleavage of active caspase-3. J Biol Chem 278:43245-43253.
23. Blandini F, Nappi G, Tassorelli C, Martignoni E (2000) Functional changes in the basal ganglia circuitry in Parkinson's disease. Prog Neurobiol 62:63-88.
24. Bonelli RM, Wenning GK (2006) Pharmacological management of Huntington's disease: An evidence- based review. Curr Pharm Des 12:2701-2720.
25. Bonifati DM, Kishore U (2007) Role of complement in neurodegeneration and neuroinflammation. Mol Immunol 44:999-1010.
26. Borland LM, Michael AC (2004) Voltammetric study of the control of striatal dopamine release by glutamate. J Neurochem 91:220-229.
27. Borovecki F, Lovrecic L, Zhou J, Jeong H, Then F, Rosas HD, Hersch SM, Hogarth P, Bouzou B, Jensen RV, Krainc D (2005) Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. Proc Natl Acad Sci USA 102:11023-11028.
28. Borrell-Pages M, Zala D, Humbert S, Saudou F (2006) Huntington's disease: from huntingtin function and dysfunction to therapeutic strategies. Cell Mol Life Sci 63:2642-2660.
29. Brotchie JM (1998) Adjuncts to dopamine replacement: A pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease. Mov Disord 13:871-876.
30. Brotchie JM (2000) The neural mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease. Ann Neurol 47:S105-S114.
31. 1 cannabinoid receptor signalling in Parkinson's disease. Curr Opin Pharmacol 3:54-61.
32. Brouillet E, Conde F, Beal MF, Hantraye P (1999) Replicating Huntington's disease phenotype in experimental animals. Prog Neurobiol 59:427-468.
33. Brouillet E, Jacquard C, Bizat N, Blum D (2005) 3-Nitropropionic acid: A mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. J Neurochem 95:1521-1540.
34. Brown TM, Brotchie JM, Fitzjohn SM (2003) Cannabinoids decrease corticostriatal synaptic transmission via an effect on glutamate uptake. J Neurosci 23:11073-11077.
35. Buckley NE, McCoy KL, Mezey E, Bonner T, Zimmer A, Felder CC, Glass M, Zimmer A (2000) Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor. Eur J Pharmacol 396:141-149.
36. Butler R, Bates GP (2006) Histone deacetylase inhibitors as therapeutics for polyglutamine disorders. Nat Rev Neurosci 7:784-796.
37. Cabin DE, Shimazu K, Murphy D, Cole NB, Gottschalk W, McIlwain KL, Orrison B, Chen A, Ellis CE, Paylor R, Lu B, Nussbaum RL (2002) Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci 22:8797-8807.
38. Cabranes A, Venderova K, de Lago E, Fezza F, Sánchez A, Mestre L, Valenti M, García-Merino A, Ramos JA, Di Marzo V, Fernández-Ruiz J (2005) Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. Neurobiol Dis 20:207-217.
39. 1 receptors in motorrelated brain structures of chronic relapsing experimental allergic encephalomyelitis mice. Brain Res 1107:199-205.
40. Cadogan AK, Alexander SP, Boyd EA, Kendall DA (1997) Influence of cannabinoids on electrically evoked dopamine release and cyclic AMP generation in the rat striatum. J Neurochem 69:1131-1137.
41. 2 dopamine receptors is required for long-term synaptic depression in the striatum. Neurosci Lett 142:95-99.
42. Calabresi P, Pisani A, Mercuri NB, Bernardi G (1996) The corticostriatal projection: from synaptic plasticity to dysfunctions of the basal ganglia. Trends Neurosci 19:19-24.
43. Calabresi P, Giacomini P, Centonze D, Bernardi G (2000) Levodopa-induced dyskinesia: A pathological form of striatal synaptic plasticity? Ann Neurol 47:60-68; discussion:68-69.
44. Carlsson A (2002) Treatment of Parkinson's with L-DOPA. The early discovery phase, and a comment on current problems. J Neural Transm 109:777-787.
45. 1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids. Neuropsychopharmacology doi:10.1038/sj. npp.1301375.
46. Carroll CB, Bain PG, Teare L, Liu X, Joint C, Wroath C, Parkin SG, Fox P, Wright D, Hobart J, Zajicek JP (2004) Cannabis for dyskinesia in Parkinson disease: A randomized double-blind crossover study. Neurology 63:1245-1250.
47. Castaneda E, Moss DE, Oddie SD, Whishaw IQ (1991) THC does not affect striatal dopamine release: Microdialysis in freely moving rats. Pharmacol Biochem Behav 40:587-591.
48. Cattaneo E, Zuccato C, Tartari M (2005) Normal huntingtin function: An alternative approach to Huntington's disease. Nat Rev Neurosci 6:919-930.
49. 2 receptors and endocannabinoids mediates the effects of cocaine on striatal GABAergic transmission. Neuropsychopharmacology 29:1488-1497.
50. Centonze D, Rossi S, Prosperetti C, Tscherter A, Bernardi G, Maccarrone M, Calabresi P (2005) Abnormal sensitivity to cannabinoid receptor stimulation might contribute to altered gammaaminobutyric acid transmission in the striatum of R6/2 Huntington's disease mice. Biol Psychiatry 57:1583-1589.
51. Centonze D, Finazzi-Agro A, Bernardi G, Maccarrone M (2007) The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Trends Pharmacol Sci 28:180-187.
52. Chan PK, Yung WH (1998) Occlusion of the presynaptic action of cannabinoids in rat substantia nigra pars reticulata by cadmium. Neurosci Lett 249:57-60.
53. Chan PK, Chan SC, Yung WH (1998) Presynaptic inhibition of GABAergic inputs to rat substantia nigra pars reticulata neurones by a cannabinoid agonist. Neuroreport 9:671-675.
54. Chevaleyre V, Takahashi KA, Castillo PE (2006) Endocannabinoid-mediated synaptic plasticity in the CNS. Annu Rev Neurosci 29:37-76.
55. 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther 277:586-594.
56. Consroe P (1998) Brain cannabinoid systems as targets for the therapy of neurological disorders. Neurobiol Dis 5:534-551.
57. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, Lichtman AH (2001) Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 98:9371-9376.
58. Crawley JN, Corwin RL, Robinson JK, Felder ChC, Devane WA, Axelrod J (1993) Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents. Pharmacol Biochem Behav 46:967-972.
59. Cristino L, de Petrocellis L, Pryce G, Baker D, Guglielmotti V, Di Marzo V (2006) Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience 139:1405-1415.
60. Curtis MA, Penney EB, Pearson AG, van Roon-Mom WM, Butterworth NJ, Dragunow M, Connor B, Faull RL (2003) Increased cell proliferation and neurogenesis in the adult human Huntington's disease brain. Proc Natl Acad Sci USA 100:9023-9027.
61. Curtis MA, Faull RL, Glass M (2006) A novel population of progenitor cells expressing cannabinoid receptors in the subependymal layer of the adult normal and Huntington's disease human brain.. J Chem Neuroanat 31:210-215.
62. Dawbarn D, Harmar AJ, Pycock CJ (1981) Intranigral injection of capsaicin enhances motor activity and depletes nigral 5-hydroxytryptamine but not substance P. Neuropharmacology 20:341-346.
63. de Lago E, Fernandez-Ruiz J, Ortega-Gutierrez S, Viso A, Lopez-Rodriguez ML, Ramos JA (2002) UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide. Eur J Pharmacol 449:99-103.
64. de Lago E, de Miguel, Lastres-Becker I, Ramos JA, Fernández-Ruiz J (2004a) Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: In vivo and in vitro evidence. Brain Res 1007:152-159.
65. de Lago E, Ligresti A, Ortar G, Morera E, Cabranes A, Pryce G, Bifulco M, Baker D, Fernández-Ruiz J, Di Marzo V (2004b) In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake. Eur J Pharmacol 484:249-257.
66. de Lago E, Urbani P, Ramos JA, Di Marzo V, Fernández-Ruiz J (2005) Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease. Brain Res 1050:210-216.
67. de Lago E, Fernández-Ruiz J, Ortega-Gutierrez S, Cabranes A, Pryce G, Baker D, Lopez- Rodriguez M, Ramos JA (2006) UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders. Eur Neuropsychopharmacol 16:7-18.
68. de Lau LM, Breteler MM (2006) Epidemiology of Parkinson's disease. Lancet Neurol 5:525-535.
69. Denovan-Wright EM, Robertson HA (2000) Cannabinoid receptor messenger RNA levels decrease in subset neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice. Neuroscience 98:705-713.
70. Desarnaud F, Cadas H, Piomelli D (1995) Anandamide amidohydrolase activity in rat brain microsomes. Identification and partial purification. J Biol Chem 270:6030-6035.
71. Dewey WL (1986) Cannabinoid pharmacology. Pharmacol Rev 38:151-178.
72. Diana MA, Marty A (2004) Endocannabinoid-mediated short-term synaptic plasticity: depolarization- induced suppression of inhibition (DSI) and depolarization-induced suppression of excitation (DSE). Br J Pharmacol 142:9-19.
73. Di Marzo V, Breivogel C, Bisogno T, Melck D, Patrick G, Tao Q, Szallasi A, Razdan RK, Martin BR (2000a) Neurobehavioral activity in mice of N-vanillyl-arachidonyl-amide. Eur J Pharmacol 406:363-374.
74. 2 receptor-mediated actions of anandamide in mouse brain. J Neurochem 75:2434-2444.
75. Di Marzo V, Hill MP, Bisogno T, Crossman AR, Brotchie JM (2000c) Enhanced levels of endocannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J 14, 1432-1438.
76. Di Marzo V, Berrendero F, Bisogno T, Gonzalez S, Cavaliere P, Romero J, Cebeira M, Ramos JA, Fernandez-Ruiz J (2000d) Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of ?9-tetrahydrocannabinol-tolerant rats. J Neurochem 74:1627-1635.
77. Di Marzo V, Lastres-Becker I, Bisogno T, De Petrocellis L, Milone A, Davis JB, Fernandez-Ruiz J (2001) Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues. Eur J Pharmacol 420:123-131.
78. Di Marzo V, Bifulco M, De Petrocellis L (2004) The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 3:771-784.
79. Di Monte DA (2003) The environment and Parkinson's disease: Is the nigrostriatal system preferentially targeted by neurotoxins? Lancet Neurol 2:531-538.
80. Dinh TP, Freund TF, Piomelli D (2002) A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem Phys Lipids 121:149-158.
81. Egertova M, Elphick MR (2000) Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C-terminal tail of CB. J Comp Neurol 422:159-171.
82. 1 cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling. Neuroscience 119:481-496.
83. Engler B, Freiman I, Urbanski M, Szabo B (2006) Effects of exogenous and endogenous cannabinoids on GABAergic neurotransmission between the caudate-putamen and the globus pallidus in the mouse. J Pharmacol Exp Ther 316:608-617.
84. Esposito G, Iuvone T, Savani C, Scuderi C, De Filippis D, Papa M, Di Marzo V, Steardo L (2007) Opposing control of cannabinoid receptor stimulation on amyloid-induced reactive gliosis: In vitro and in vivo evidence. J Pharmacol Exp Ther 322:1144-1152.
85. Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG (2007) Levodopa-induced dyskinesias. Mov Disord 22:1379-1389.
86. Factor SA, Friedman JH (1997) The emerging role of clozapine in the treatment of movement disorders. Mov Disord 12:483-496.
87. Felder CC, Glass M (1998) Cannabinoid receptors and their endogenous agonists. Annu Rev Pharmacol Toxicol 38:179-200.
88. Fernández-Espejo E, Caraballo I, Rodriguez de Fonseca F, Ferrer B, El Banoua F, Flores JA, Galan-Rodriguez B (2004) Experimental parkinsonism alters anandamide precursor synthesis, and functional deficits are improved by AM404: A modulator of endocannabinoid function. Neuropsychopharmacology 29:1134-1142.
89. Fernández-Espejo E, Caraballo I, de Fonseca FR, El Banoua F, Ferrer B, Flores JA, Galan- Rodriguez B (2005) Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism. Neurobiol Dis 18:591-601.
90. Fernández-Ruiz J, González S (2005) Cannabinoid control of motor function at the basal ganglia. In: Pertwee RG (ed.), Handbook of Experimental Pharmacology - 168 - Cannabinoids. Heidelberg: Springer-Verlag, pp. 479-507.
91. Fernandez-Ruiz J, Lastres-Becker I, Cabranes A, Gonzalez S, Ramos JA (2002) Endocannabinoids and basal ganglia functionality. Prostaglandins Leukot Essent Fatty Acids 66:257-267.
92. Fernández-Ruiz J, González S, Romero J, Ramos JA (2005) Cannabinoids in neurodegeneration and neuroprotection. In: Mechoulam R (ed.), Cannabinoids as Therapeutics (MDT). Switzerland: Birkhaüser Verlag, pp. 79-109.
93. 2 receptor: A new target for the control of neural cell survival? Trends Pharmacol Sci 28:39-45.
94. Ferrer B, Asbrock N, Kathuria S, Piomelli D, Giuffrida A (2003) Effects of levodopa on endocannabinoid levels in rat basal ganglia: Implications for the treatment of levodopa-induced dyskinesias. Eur J Neurosci 18:1607-1614.
95. Fitzpatrick JS, Akopian G, Walsh JP (2001) Short-term plasticity at inhibitory synapses in rat striatum and its effects on striatal output. J Neurophysiol 85:2088-2099.
96. Fowler CJ (2005) Pharmacological properties and therapeutic possibilities for drugs acting upon endocannabinoid receptors. Curr Drug Targets CNS Neurol Disord 4:685-696.
97. Fowler CJ, Holt S, Nilsson O, Jonsson KO, Tiger G, Jacobsson SO (2005) The endocannabinoid signaling system: pharmacological and therapeutic aspects. Pharmacol Biochem Behav 81:248-262.
98. Fox SH, Henry B, Hill M, Crossman A, Brotchie J (2002a) Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov Disord 17:1180-1187.
99. Fox SH, Kellett M, Moore AP, Crossman AR, Brotchie JM (2002b) Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Mov Disord 17:145-149.
100. Freiman I, Szabo B (2005) Cannabinoids depress excitatory neurotransmission between the subthalamic nucleus and the globus pallidus. Neuroscience 133:305-313.
101. Freiman I, Anton A, Monyer H, Urbanski MJ, Szabo B (2006) Analysis of the effects of cannabinoids on identified synaptic connections in the caudate-putamen by paired recordings in transgenic mice. J Physiol 575:789-806.
102. French ED, Dillon K, Wu X (1997) Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neuroreport 8:649-652.
103. Freund TF, Katona I, Piomelli D (2003) Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83:1017-1066.
104. Fride E, Mechoulam R (1993) Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur J Pharmacol 231:313-314.
105. Fusco FR, Martorana A, Giampa C, De March Z, Farini D, D'Angelo V, Sancesario G, Bernardi G (2004) Immunolocalization of CB1 receptor in rat striatal neurons: A confocal microscopy study. Synapse 53:159-167.
106. Galante M, Diana MA (2004) Group I metabotropic glutamate receptors inhibit GABA release at interneuron-Purkinje cell synapses through endocannabinoid production. J Neurosci 24:4865-4874.
107. Galas MC, Bizat N, Cuvelier L, Bantubungi K, Brouillet E, Schiffmann SN, Blum D (2004) Death of cortical and striatal neurons induced by mitochondrial defect involves differential molecular mechanisms. Neurobiol Dis 15:152-159.
108. Galve-Roperh I, Aguado T, Rueda D, Velasco G, Guzman M (2006) Endocannabinoids: A new family of lipid mediators involved in the regulation of neural cell development. Curr Pharm Des 12:2319-2325.
109. Galve-Roperh I, Aguado T, Palazuelos J, Guzman M (2007) The endocannabinoid system and neurogenesis in health and disease. Neuroscientist 13:109-114.
110. Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, Liu B (2002) Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J Neurochem 81:1285-1297.
111. García-Arencibia M, González S, de Lago E, Ramos JA, Mechoulam R, Fernández-Ruiz J (2007) Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: Importance of antioxidant and cannabinoid receptor-independent properties. Brain Res 1134:162-170.
112. 1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J Neurophysiol 85:468-471.
113. Gerdeman GL, Ronesi J, Lovinger DM (2002) Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nat Neurosci 5:446-451.
114. Gerdeman GL, Partridge JG, Lupica CR, Lovinger DM (2003) It could be habit forming: drugs of abuse and striatal synaptic plasticity. Trends Neurosci 26:184-192.
115. 1 antagonist rimonabant. Symposium on the Cannabinoids International Cannabinoid Research Society (Burlington, VT), p. 178.
116. 1 receptors. Eur J Pharmacol 341:39-44.
117. Gifford AN, Samiian L, Gatley SJ, Ashby Jr CR (1997) Examination of the effect of the cannabinoid receptor agonist, CP 55, 940, on electrically evoked transmitter release from rat brain slices. Eur J Pharmacol 324:187-192.
118. Gispert S, Del Turco D, Garrett L, Chen A, Bernard DJ, Hamm-Clement J, Korf HW, Deller T, Braak H, Auburger G, Nussbaum RL (2003) Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation. Mol Cell Neurosci 24:419-429.
119. Giuffrida A, Parsons LH, Kerr TM, Rodriguez de Fonseca F, Navarro M, Piomelli D (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 2:358-363.
120. Giuffrida A, Beltramo M, Piomelli D (2001) Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. J Pharmacol Exp Ther 298:7-14.
121. Glass M, Faull RLM, Dragunow M (1993) Loss of cannabinoid receptors in the substantia nigra in Huntington's disease. Neuroscience 56:523-527.
122. Glass M, Dragunow M, Faull RL (1997) Cannabinoid receptors in the human brain: A detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 77:299-318.
123. Glass M, Dragunow M, Faull RL (2000) The pattern of neurodegeneration in Huntington's disease: A comparative study of cannabinoid, dopamine, adenosine and GABA-A receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 97:505-519.
124. 1 receptors. Neuroscience 123:207-212.
125. 2 receptors: Immunohistochemical localization in rat brain. Brain Res 1071:10-23.
126. González S, Romero J, de Miguel R, Lastres-Becker I, Villanúa MA, Makriyannis A, Ramos JA, Fernández-Ruiz J (1999) Extrapyramidal and neuroendocrine effects of AM404, an inhibitor of the carrier-mediated transport of anandamide. Life Sci 65:327-336.
127. 1 receptors in the basal ganglia and motor response to activation or blockade of these receptors in parkin-null mice. Brain Res 1046:195-206.
128. 1 receptor antagonist, in a rat model of Parkinson's disease. Brain Res 1073-1074:209-219.
129. 9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats. Eur J Pharmacol 365:133-142.
130. Graybiel AM (2005) The basal ganglia: learning new tricks and loving it. Curr Opin Neurobiol 15:638-644.
131. Graybiel AM, Rauch SL (2000) Toward a neurobiology of obsessive-compulsive disorder. Neuron 28:343-347.
132. Graybiel AM, Aosaki T, Flaherty AW, Kimura M (1994) The basal ganglia and adaptive motor control. Science 265:1826-1831.
133. Gu M, Gash MT, Mann VM, Javoy-Agid F, Cooper JM, Schapira AH (1996) Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol 39:385-389.
134. Gubellini P, Saulle E, Centonze D, Bonsi P, Pisani A, Bernardi G, Conquet F, Calabresi P (2001) Selective involvement of mGlu1 receptors in corticostriatal LTD. Neuropharmacology 40:839-846.
135. Gubellini P, Picconi B, Bari M, Battista N, Calabresi P, Centonze D, Bernardi G, Finazzi-Agro A, Maccarrone M (2002) Experimental parkinsonism alters endocannabinoid degradation: Implications for striatal glutamatergic transmission. J Neurosci 22:6900-6907.
136. 1 cannabinoid receptor antagonist SR 141716A affects A9 dopamine neuronal activity in the rat. Neuroreport 6:1421-1425.
137. Hajos M, Engberg G, Nissbrandt H, Magnusson T, Carlsson A (1988) Capsaicin-sensitive vasodilatatory mechanisms in the rat substantia nigra and striatum. J Neural Transm 74:129-139.
138. 9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 95:8268-8273.
139. 2, a peripheral cannabinoid receptor. Proc Natl Acad Sci USA 96:14228-14233.
140. 2+-assisted receptor-driven endocannabinoid release: Mechanisms that associate presynaptic and postsynaptic activities. Curr Opin Neurobiol 17:360-365.
141. 9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance. Neuropharmacology 52:1079-1087.
142. Hemming M, Yellowlees PM (1993) Effective treatment of Tourette's syndrome with marijuana. J Psychopharmacol 7:389-391.
143. Henneberger C, Redman SJ, Grantyn R (2007) Cortical efferent control of subcortical sensory neurons by synaptic disinhibition. Cereb Cortex 17:2039-2049.
144. Herkenham M, Lynn AB, de Costa BR, Richfield EK (1991a) Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res 547:267-274.
145. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC (1991b) Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study. J Neurosci 11:563-583.
146. Hersch SM, Ferrante RJ (1997) Neuropathology and pathophysiology of Huntington's disease. In: Watts RL, Koller WC (eds.), Movement Disorders. Neurologic Principles and Practice. New York: McGraw-Hill, pp. 503-518.
147. Hiltunen AJ, Jarbe TU, Wangdahl K (1988) Cannabinol and cannabidiol in combination: Temperature, open-field activity, and vocalization. Pharmacol Biochem Behav 30:675-678.
148. Hockly E, Cordery PM, Woodman B, Mahal A, van Dellen A, Blakemore C, Lewis CM, Hannan AJ, Bates GP (2002) Environmental enrichment slows disease progression in R6/2 Huntington's disease mice. Ann Neurol 51:235-242.
149. 1 receptor mRNA in neuronal subpopulations of rat striatum: A double-label in situ hybridization study. Synapse 37:71-80.
150. Huang CC, Lo SW, Hsu KS (2001) Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons. J Physiol 532:731-748.
151. 2 receptor ligands. Mini Rev Med Chem 5:641-649.
152. 1 receptor mRNA in basal ganglia of normal and parkinsonian human brain. J Neural Transm 110:1279-1288.
153. Itier JM, Ibanez P, Mena MA, Abbas N, Cohen-Salmon C, Bohme GA, Laville M, Pratt J, Corti O, Pradier L, Ret G, Joubert C, Periquet M, Araujo F, Negroni J, Casarejos MJ, Canals S, Solano R, Serrano A, Gallego E, Sanchez M, Denefle P, Benavides J, Tremp G, Rooney TA, Brice A, Garcia de Yebenes J (2003) Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum Mol Genet 12:2277-2291.
154. Iuvone T, Esposito G, Esposito R, Santamaria R, Di Rosa M, Izzo AA (2004) Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloidinduced toxicity in PC12 cells. J Neurochem 89:134-141.
155. 9-tetrahydrocannabinol and (R)-methanandamide on open-field behavior in rats. Behav Pharmacol 9:169-174.
156. Jayamanne A, Greenwood R, Mitchell VA, Aslan S, Piomelli D, Vaughan CW (2006) Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol 147:281-288.
157. Jin K, LaFevre-Bernt M, Sun Y, Chen S, Gafni J, Crippen D, Logvinova A, Ross CA, Greenberg DA, Ellerby LM (2005) FGF-2 promotes neurogenesis and neuroprotection and prolongs survival in a transgenic mouse model of Huntington's disease. Proc Natl Acad Sci USA 102:18189-18194.
158. Julian MD, Martin AB, Cuellar B, Rodriguez De Fonseca F, Navarro M, Moratalla R, Garcia- Segura LM (2003) Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia. Neuroscience 119:309-318.
159. Jung KM, Mangieri R, Stapleton C, Kim J, Fegley D, Wallace M, Mackie K, Piomelli D (2005) Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors. Mol Pharmacol 68:1196-1202.
160. Kalant H (2004) Adverse effects of cannabis on health: An update of the literature since 1996. Prog Neuropsychopharmacol Biol Psychiatry 28:849-863.
161. Kaneda K, Kita T, Kita H (2007) Repetitive activation of glutamatergic inputs evokes a long-lasting excitation in rat globus pallidus neurons in vitro. J Neurophysiol 97:121-133.
162. 1 receptor-mediated inhibition of NMDA- And kainate-stimulated noradrenaline and dopamine release in the brain. Naunyn Schmiedebergs Arch Pharmacol 359:466-470.
163. 2 receptors enhances heterodimer formation: A mechanism for receptor cross-talk? Mol Pharmacol 67:1697-1704.
164. Kieburtz K (1999) Antiglutamate therapies in Huntington's disease. J Neural Transm Suppl 55:97-102.
165. Kim WG, Mohney RP, Wilson B, Jeohn GH, Liu B, Hong JS (2000) Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J Neurosci 20:6309-6316.
166. Kim SR, Lee DY, Chung ES, Oh UT, Kim SU, Jin BK (2005) Transient receptor potential vanilloid subtype 1 mediates cell death of mesencephalic dopaminergic neurons in vivo and in vitro. J Neurosci 25:662-671.
167. Köfalvi A, Rodrigues RJ, Ledent C, Mackie K, Vizi ES, Cunha RA, Sperlagh B (2005) Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: A combined immunochemical and pharmacological analysis. J Neurosci 25:2874-2884.
168. Koos T, Tepper JM (1999) Inhibitory control of neostriatal projection neurons by GABAergic interneurons. Nat Neurosci 2:467-472.
169. Kreitzer AC, Malenka RC (2005) Dopamine modulation of state-dependent endocannabinoid release and long-term depression in the striatum. J Neurosci 25:10537-10545.
170. Kreitzer AC, Malenka RC (2007) Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature 445:643-647.
171. Kurlan R, Richard IH, Papka M, Marshall F (2000) Movement disorders in Alzheimer's disease: More rigidity of definitions is needed. Mov Disord 15:24-29.
172. Lastres-Becker I, Fernandez-Ruiz J (2006) An overview of Parkinson's disease and the cannabinoid system and possible benefits of cannabinoid-based treatments. Curr Med Chem 13:3705-3718.
173. 1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. Eur J Neurosci 14:1827-1832.
174. Lastres-Becker I, Fezza F, Cebeira M, Bisogno T, Ramos JA, Milone A, Fernández-Ruiz J, Di Marzo V (2001b) Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease. Neuroreport 12:2125-2129.
175. Lastres-Becker I, Hansen HH, Berrendero F, de Miguel R, Pérez-Rosado A, Manzanares J, Ramos JA, Fernández-Ruiz J (2002a) Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease. Synapse 44:23-35.
176. 1 receptors in the basal ganglia in the late akinetic phase of rats with experimental Huntington's disease. Neurotox Res 4:601-608.
177. 1 receptors in the basal ganglia of a transgenic model of Huntington's disease. Brain Res 929:236-242.
178. Lastres-Becker I, de Miguel R, De Petrocellis L, Makriyannis A, Di Marzo V, Fernández-Ruiz J (2003a) Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease. J Neurochem 84:1097-1109.
179. Lastres-Becker I, De Miguel R, Fernández-Ruiz J (2003b) The endocannabinoid system and Huntington's disease. Curr Drug Targets CNS Neurol Disord 2:335-347.
180. Lastres-Becker I, Bizat N, Boyer F, Hantraye P, Brouillet E, Fernández-Ruiz J (2003c) Effects of cannabinoids in the rat model of Huntington's disease generated by an intrastriatal injection of malonate. Neuroreport 14:813-816.
181. Lastres-Becker I, Bizat N, Boyer F, Hantraye P, Fernández-Ruiz J, Brouillet E (2004) Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo. Neuroreport 15:2375-2379.
182. Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernández-Ruiz J (2005) Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol Dis 19:96-107.
183. Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernández-Ruiz J (2005) Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson.
184. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, Böhme GA, Imperato A, Pedrazzini T, Roques BP, Vassart G, Fratta W, Parmentier M (1999) Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283:401-404.
185. Lee J, Di Marzo V, Brotchie JM (2006) A role for vanilloid receptor 1 (TRPV1) and endocannabinnoid signalling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats. Neuropharmacology 51:557-565.
186. Li SH, Li XJ (2004) Huntingtin and its role in neuronal degeneration. Neuroscientist 10:467-475.
187. Li S, Li XJ (2006) Multiple pathways contribute to the pathogenesis of Huntington disease. Mol Neurodegener 1:19.
188. Lichtman AH, Hawkins EG, Griffin G, Cravatt BF (2002) Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo. J Pharmacol Exp Ther 302:73-79.
189. Lupica CR, Riegel AC (2005) Endocannabinoid release from midbrain dopamine neurons: A potential substrate for cannabinoid receptor antagonist treatment of addiction. Neuropharmacology 48:1105-1116.
190. Maccarrone M, Gubellini P, Bari M, Picconi B, Battista N, Centonze D, Bernardi G, Finazzi-Agro A, Calabresi P (2003) Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism. J Neurochem 85:1018-1025.
191. Maccarrone M, Battista N, Centonze D (2007) The endocannabinoid pathway in Huntington's disease: A comparison with other neurodegenerative diseases. Prog Neurobiol 81:349-379.
192. Mackie K (2005) Distribution of cannabinoid receptors in the central and peripheral nervous system. In: Pertwee RG (ed.), Handbook of Experimental Pharmacology - 168 - Cannabinoids. Heidelberg: Springer-Verlag, pp. 299-325.
193. Mailleux P, Vanderhaeghen JJ (1992a) Distribution of neuronal cannabinoid receptor in the adult rat brain: A comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience 48:655-668.
194. Mailleux P, Vanderhaeghen JJ (1992b) Age-related loss of cannabinoid of cannabinoid receptor binding sites and mRNA in the rat striatum. Neurosci Lett 147:179-181.
195. Mailleux P, Vanderhaeghen JJ (1993) Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: An in situ hybridization study. J Neurochem 61:1705-1712.
196. Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R, Feldmann M (2000) The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA 97:9561-9566.
197. Maneuf YP, Crossman AR, Brotchie JM (1996a) Modulation of GABAergic transmission in the globus pallidus by the synthetic cannabinoid WIN 55, 212-2. Synapse 22:382-385.
198. 9-THC reduces GABA uptake in the globus pallidus. Eur J Pharmacol 308:161-164.
199. 1, dopamine receptor-mediated alleviation of akinesia in the reserpinetreated rat model of Parkinson's disease. Exp Neurol 148:265-270.
200. Marinelli S, Di Marzo V, Berretta N, Matias I, Maccarrone M, Bernardi G, Mercuri NB (2003) Presynaptic facilitation of glutamatergic synapses to dopaminergic neurons of the rat substantia nigra by endogenous stimulation of vanilloid receptors. J Neurosci 23:3136-3144.
201. 1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci 11:4213-4225.
202. Matyas F, Yanovsky Y, Mackie K, Kelsch W, Misgeld U, Freund TF (2006) Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia. Neuroscience 137:337-361.
203. McCaw EA, Hu H, Gomez GT, Hebb AL, Kelly ME, Denovan-Wright EM (2004) Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice. Eur J Biochem 271:4909-4920.
204. McGeer PL, Yasojima K, McGeer EG (2001) Inflammation in Parkinson's disease. Adv Neurol 86:83-89.
205. 9-tetrahydrocannabinol. Pharmacol Biochem Behav 66:803-809.
206. Mechoulam R, Parker LA, Gallily R (2002) Cannabidiol: An overview of some pharmacological aspects. J Clin Pharmacol 42:11S-19S.
207. Melis M, Pistis M, Perra S, Muntoni AL, Pillolla G, Gessa GL (2004a) Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. J Neurosci 24:53-62.
208. Melis M, Perra S, Muntoni AL, Pillolla G, Lutz B, Marsicano G, Di Marzo V, Gessa GL, Pistis M (2004b) Prefrontal cortex stimulation induces 2-arachidonoyl-glycerol-mediated suppression of excitation in dopamine neurons. J Neurosci 24:10707-10715.
209. Melis M, Pillolla G, Bisogno T, Minassi A, Petrosino S, Perra S, Muntoni AL, Lutz B, Gessa GL, Marsicano G, Di Marzo V, Pistis M (2006) Protective activation of the endocannabinoid system during ischemia in dopamine neurons. Neurobiol Dis 24:15-27.
210. Meschler JP, Howlett AC, Madras BK (2001) Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1, 2, 5, 6-tetrahydropyridine (MPTP)- Treated non-human primates. Psychopharmacology 156:79-85.
211. Mesnage V, Houeto JL, Bonnet AM, Clavier I, Arnulf I, Cattelin F, Le Fur G, Damier P, Welter ML, Agid Y (2004) Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson's disease. Clin Neuropharmacol 27:108-110.
212. 1-like immunoreactivity, in the central nervous system of the rat and human. Proc Natl Acad Sci USA 97:3655-3660.
213. Miller AS, Walker JM (1995) Effects of a cannabinoid on spontaneous and evoked neuronal activity in the substantia nigra pars reticulata. Eur J Pharmacol 279:179-185.
214. Miller AS, Walker JM (1996) Electrophysiological effects of a cannabinoid on neural activity in the globus pallidus. Eur J Pharmacol 304:29-35.
215. Miller AS, Walker JM (1998) Local effects of cannabinoids on spontaneous activity and evoked inhibition in the globus pallidus. Eur J Pharmacol 352:199-205.
216. Milton NG (2002) Anandamide and noladin ether prevent neurotoxicity of the human amyloidbeta peptide. Neurosci Lett 332:127-130.
217. Morale MC, Serra PA, L'episcopo F, Tirolo C, Caniglia S, Testa N, Gennuso F, Giaquinta G, Rocchitta G, Desole MS, Miele E, Marchetti B (2006) Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration. Neuroscience 138:869-878.
218. Moriello AS, Balas L, Ligresti A, Cascio MG, Durand T, Morera E, Ortar G, Di Marzo V (2006) Development of the first potential covalent inhibitors of anandamide cellular uptake. J Med Chem 49:2320-2332.
219. Moss DE, McMaster SB, Rogers J (1981) Tetrahydrocannabinol potentiates reserpine-induced hypokinesia. Pharmacol Biochem Behav 15:779-783.
220. Müller-Vahl KR (2003) Cannabinoids reduce symptoms of Tourette's syndrome. Expert Opin Pharmacother 4:1717-1725.
221. Müller-Vahl KR, Kolbe H, Schneider U, Emrich HM (1998) Cannabinoids: posible role in the pathophysiology of Gilles de la Tourette-syndrome. Acta Psychiatr Scand 98:502-506.
222. 9-tetrahydrocannabinol. Am J Psychiatry 156:495.
223. Müller-Vahl KR, Schneider U, Emrich HM (1999b) Nabilone increases choreatic movements in Huntington's disease. Mov Disord 14:1038-1040.
224. Müller-Vahl KR, Kolbe H, Schneider U, Emrich HM (1999c) Cannabis in movement disorders. Forsch Komplementärned 6:23-27.
225. 9-tetrahydrocannabinol (THC): A randomized crossover trial. Pharmacopsychiatry 35:57-61.
226. Nagatsu T, Mogi M, Ichinose H, Togari A (2000) Changes in cytokines and neurotrophins in Parkinson's disease. J Neural Transm 60:277-290.
227. Narushima M, Hashimoto K, Kano M (2006a) Endocannabinoid-mediated short-term suppression of excitatory synaptic transmission to medium spiny neurons in the striatum. Neurosci Res 54:159-164.
228. Narushima M, Uchigashima M, Hashimoto K, Watanabe M, Kano M (2006b) Depolarizationinduced suppression of inhibition mediated by endocannabinoids at synapses from fastspiking interneurons to medium spiny neurons in the striatum. Eur J Neurosci 24:2246-2252.
229. Narushima M, Uchigashima M, Fukaya M, Matsui M, Manabe T, Hashimoto K, et al. (2007) Tonic enhancement of endocannabinoid-mediated retrograde suppression of inhibition by cholinergic interneuron activity in the striatum. J Neurosci 27:496-506.
230. 9-tetrahydrocannabinol: possible involvement of nigrostriatal dopaminergic alterations. Pharmacol Biochem Behav 45:291-298.
231. Naver B, Stub C, Moller M, Fenger K, Hansen AK, Hasholt L, Sorensen SA (2003) Molecular and behavioral analysis of the R6/1 Huntington's disease transgenic mouse. Neuroscience 122:1049-1057.
232. Ng Cheong Ton JM, Gerhardt GA, Friedemann M, Etgen AM, Rose GM, Sharpless NS, Gardner EL (1988) The effects of delta 9-tetrahydrocannabinol on potassium-evoked release of dopamine in the rat caudate nucleus: An in vivo electrochemical and in vivo microdialysis study. Brain Res 451:59-68.
233. 2 receptors are expressed by perivascular microglial cells in the human brain: An immunohistochemical study. Synapse 53:208-213.
234. Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N (2004) Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem 279:5298-5305.
235. Page KJ, Besret L, Jain M, Monaghan EM, Dunnett SB, Everitt BJ (2000) Effects of systemic 3-nitropropionic acid-induced lesions of the dorsal striatum on cannabinoid and mu-opioid receptor binding in the basal ganglia. Exp Brain Res 130:142-150.
236. Pavese N, Gerhard A, Tai YF, Ho AK, Turkheimer F, Barker RA, Brooks DJ, Piccini P (2006) Microglial activation correlates with severity in Huntington disease: A clinical and PET study. Neurology 66:1638-1643.
237. Pazos MR, Nuñez E, Benito C, Tolón R, Romero J (2004) Role of the endocannabinoid system in Alzheimer's disease: new perspectives. Life Sci 75:1907-1915.
238. Pertwee RG (2002) Cannabinoids and multiple sclerosis. Pharmacol Ther 95:165-174.
239. Pertwee RG, Wickens AP (1991) Enhancement by chlordiazepoxide of catalepsy induced in rats by intravenous or intrapallidal injections of enantiomeric cannabinoids. Neuropharmacology 30:237-244.
240. 9-tetrahydrocannabinol to produce marked catalepsy in mice. Neuropharmacology 27:1265-1270.
241. Pintor A, Tebano MT, Martire A, Grieco R, Galluzzo M, Scattoni ML, Pezzola A, Coccurello R, Felici F, Cuomo V, Piomelli D, Calamandrei G, Popoli P (2006) The cannabinoid receptor agonist WIN 55, 212-2 attenuates the effects induced by quinolinic acid in the rat striatum. Neuropharmacology 51:1004-1012.
242. Pisani A, Fezza F, Galati S, Battista N, Napolitano S, Finazzi-Agro A, Bernardi G, Brusa L, Pierantozzi M, Stanzione P, Maccarrone M (2005) High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients. Ann Neurol 57:777-779.
243. Ploner CJ, Tschirch A, Ostendorf F, Dick S, Gaymard BM, Rivaud-Pechoux S, et al. (2002) Oculomotor effects of delta-9-tetrahydrocannabinol in humans: Implications for the functional neuroanatomy of the brain cannabinoid system. Cereb Cortex 12:1016-1023.
244. 1-independent inhibition of dopamine transporter activity by cannabinoids in mouse dorsal striatum. J Neurochem 101:389-396.
245. Rajkowska G, Selemon LD, Goldman-Rakic PS (1998) Neuronal and glial somal size in the prefrontal cortex: A postmortem morphometric study of schizophrenia and Huntington disease. Arch Gen Psychiatry 55:215-224.
246. Ramirez BG, Blazquez C, Gomez del Pulgar T, Guzman M, de Ceballos ML (2005) Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 25:1904-1913.
247. Richfield EK, Herkenham M (1994) Selective vulnerability in Huntington's disease: preferential loss of cannabinoid receptors in lateral globus pallidus. Ann Neurol 36:577-584.
248. Richter A, Loscher W (1994) (+)-WIN 55, 212-2, a novel cannabinoid receptor agonist, exerts antidystonic effects in mutant dystonic hamsters. Eur J Pharmacol 264:371-377.
249. Richter A, Loscher W (2002) Effects of pharmacological manipulations of cannabinoid receptors on severity of dystonia in a genetic model of paroxysmal dyskinesia. Eur J Pharmacol 454:145-151.
250. Riegel AC, Lupica CR (2004) Independent presynaptic and postsynaptic mechanisms regulate endocannabinoid signaling at multiple synapses in the ventral tegmental area. J Neurosci 24:11070-11078.
251. Riley BE, Orr HT (2006) Polyglutamine neurodegenerative diseases and regulation of transcription: Assembling the puzzle. Genes Dev 20:2183-2192.
252. Robbe D, Alonso G, Duchamp F, Bockaert J, Manzoni OJ (2001) Localization and mechanisms of action of cannabinoid receptors at the glutamatergic synapses of the mouse nucleus accumbens. J Neurosci 21:109-116.
253. Robbe D, Kopf M, Remaury A, Bockaert J, Manzoni OJ (2002) Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. Proc Natl Acad Sci USA 99:8384-8388.
254. 9-tetrahydrocannabinol treatment. Pharmacol Biochem Behav 47:33-40.
255. Rodriguez de Fonseca F, Del Arco I, Martin-Calderon JL, Gorriti MA, Navarro M (1998) Role of the endogenous cannabinoid system in the regulation of motor activity. Neurobiol Dis 5:483-501.
256. 1 cannabinoid receptor in mu- opioid receptor patches of the rat Caudate putamen nucleus. J Neurosci 21:823-833.
257. Romero J, García L, Cebeira M, Zadrozny D, Fernández-Ruiz J, Ramos JA (1995a) The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behaviour: role of nigrostriatal dopaminergic neurons. Life Sci 56:2033-2040.
258. Romero J, de Miguel R, García-Palomero E, Fernández-Ruiz J, Ramos JA (1995b) Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal function. Brain Res 694:223-232.
259. Romero J, Garcia-Palomero E, Fernandez-Ruiz JJ, Ramos JA (1996a) Involvement of GABAB receptors in the motor inhibition produced by agonists of brain cannabinoid receptors. Behav Pharmacol 7:299-302.
260. 1 receptor ligand. Life Sci 58:1249-1257.
261. Romero J, de Miguel R, Ramos JA, Fernández-Ruiz J (1998a) The activation of cannabinoid receptors in striatonigral neurons inhibited GABA uptake. Life Sci 62:351-363.
262. Romero J, Berrendero F, García-Gil L, de la Cruz P, Ramos JA, Fernández-Ruiz J (1998b) Loss of cannabinoid receptor binding and messenger RNA levels and cannabinoid agonist-stimulated [35S]-GTPγS binding in the basal ganglia of aged rats. Neuroscience 84:1075-1083.
263. Romero J, Berrendero F, Pérez-Rosado A, Manzanares J, Rojo A, Fernández-Ruiz J, de Yébenes JG, Ramos JA (2000) Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen. Life Sci 66:485-494.
264. Romero J, Lastres-Becker I, de Miguel R, Berrendero F, Ramos JA, Fernandez-Ruiz J (2002) The endogenous cannabinoid system and the basal ganglia. Biochemical, pharmacological, and therapeutic aspects. Pharmacol Ther 95:137-152.
265. Ronesi J, Lovinger DM (2005) Induction of striatal long-term synaptic depression by moderate frequency activation of cortical afferents in rat. J Physiol 562:245-256.
266. Ronesi J, Gerdeman GL, Lovinger DM (2004) Disruption of endocannabinoid release and striatal long-term depression by postsynaptic blockade of endocannabinoid membrane transport. J Neurosci 24:1673-1679.
267. Russo E, Guy GW (2006) A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 66:234-246.
268. Sagredo O, Ramos JA, Decio A, Mechoulam R, Fernández-Ruiz J (2007) Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid receptors. Eur J Neurosci Eur J Neuro Sci 26:843-851.
269. Sañudo-Peña MC, Walker JM (1997) Role of the subthalamic nucleus in cannabinoid actions in the substantia nigra of the rat. J Neurophysiol 77:1635-1638.
270. Sañudo-Peña MC, Patrick SL, Patrick RL, Walker JM (1996) Effects of intranigral cannabinoids on rotational behavior in rats: Interactions with the dopaminergic system. Neurosci Lett 206:21-24.
271. Sañudo-Peña MC, Force M, Tsou K, Miller AS, Walker JM (1998a) Effects of intrastriatal cannabinoids on rotational behavior in rats: Interactions with the dopaminergic system. Synapse 30:221-226.
272. Sañudo-Peña MC, Patrick SL, Khen S, Patrick RL, Tsou K, Walker JM (1998b) Cannabinoid effects in basal ganglia in a rat model of Parkinson's disease. Neurosci Lett 248:171-174.
273. Sañudo-Peña MC, Tsou K, Walker JM (1999) Motor actions of cannabinoids in the basal ganglia output nuclei. Life Sci 65:703-713.
274. Sañudo-Peña MC, Tsou K, Romero J, Mackie K, Walker JM (2000a) Role of the superior colliculus in the motor effects of cannabinoids and dopamine. Brain Res 853:207-214.
275. Sañudo-Peña MC, Romero J, Seale GE, Fernandez-Ruiz JJ, Walker JM (2000b) Activational role of cannabinoids on movement. Eur J Pharmacol 391:269-274.
276. Sapp E, Kegel KB, Aronin N, Hashikawa T, Uchiyama Y, Tohyama K, Bhide PG, Vonsattel JP, DiFiglia M (2001) Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol 60:161-172.
277. Sarne Y, Mechoulam R (2005) Cannabinoids: between neuroprotection and neurotoxicity. Curr Drug Targets CNS Neurol Disord 4:677-684.
278. Schoffelmeer AN, Hogenboom F, Wardeh G, De Vries TJ (2006) Interactions between CB1 cannabinoid and mu opioid receptors mediating inhibition of neurotransmitter release in rat nucleus accumbens core. Neuropharmacology 51:773-781.
279. Schultz W (2006) Behavioral theories and the neurophysiology of reward. Annu Rev Psychol 57:87-115.
280. 1)-receptors in mice. Neurosci Lett 326:196-200.
281. 1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpinetreated rat model of Parkinson's disease. Mov Disord 18:138-149.
282. Sethi KD (2002) Clinical aspects of Parkinson disease. Curr Opin Neurol 15:457-460.
283. Sherer TB, Betarbet R, Greenamyre JT (2001) Pathogenesis of Parkinson's disease. Curr Opin Investig Drugs 2:657-662.
284. Sieradzan KA, Fox SH, Hill M, Dick JP, Crossman AR, Brotchie JM (2001) Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: A pilot study. Neurology 57:2108-2111.
285. 1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease. Exp Neurol 169:400-406.
286. Singhrao SK, Neal JW, Morgan BP, Gasque P (1999) Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease. Exp Neurol 159:362-376.
287. Singh N, Pillay V, Choonara YE (2007) Advances in the treatment of Parkinson's disease. Prog Neurobiol 81:29-44.
288. Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, Martin BR (1994) The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther 270:219-227.
289. Souilhac J, Poncelet M, Rinaldi-Carmona M, Le-Fur G, Soubrie P (1995) Intrastriatal injection of cannabinoid receptor agonists induced turning behavior in mice. Pharmacol Biochem Behav 51:3-7.
290. Stella N (2004) Cannabinoid signaling in glial cells. Glia 48:267-277.
291. Sung KW, Choi S, Lovinger DM (2001) Activation of group I mGluRs is necessary for induction of long-term depression at striatal synapses. J Neurophysiol 86:2405-2412.
292. Szabo B, Dorner L, Pfreundtner C, Norenberg W, Starke K (1998) Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum. Neuroscience 85:395-403.
293. Szabo B, Muller T, Koch H (1999) Effects of cannabinoids on dopamine release in the corpus striatum and the nucleus accumbens in vitro. J Neurochem 73:1084-1089.
294. Szabo B, Wallmichrath I, Mathonia P, Pfreundtner C (2000) Cannabinoids inhibit excitatory neurotransmission in the substantia nigra pars reticulata. Neuroscience 97:89-97.
295. Szabo B, Urbanski MJ, Bisogno T, Di Marzo V, Mendiguren A, Baer WU, et al. (2006) Depolarization-induced retrograde synaptic inhibition in the mouse cerebellar cortex is mediated by 2-arachidonoylglycerol. J Physiol 577:263-280.
296. Tang K, Low MJ, Grandy DK, Lovinger DM (2001) Dopamine-dependent synaptic plasticity in striatum during in vivo development. Proc Natl Acad Sci USA 98:1255-1260.
297. Taupin P, Gage FH (2002) Adult neurogenesis and neural stem cells of the central nervous system in mammals. J Neurosci Res 69:745-749.
298. Tepper J MaP, D (2006) Microcircuits in the striatum: Striatal cell types and their interaction. In: Grillner SaG, A.M., (ed.), Microcircuits: The Interface between Neurons and Global Brain Function. Cambridge, MA: The MIT Press.
299. Tersigni TJ, Rosenberg HC (1996) Local pressure application of cannabinoid agonists increases spontaneous activity of rat substantia nigra pars reticulata neurons without affecting response to iontophoretically-applied GABA. Brain Res 733:184-192.
300. Toulmond S, Tang K, Bureau Y, Ashdown H, Degen S, O'Donnell R, Tam J, Han Y, Colucci J, Giroux A, Zhu Y, Boucher M, Pikounis B, Xanthoudakis S, Roy S, Rigby M, Zamboni R, Robertson GS, Ng GY, Nicholson DW, Fluckiger JP (2004) Neuroprotective effects of M826, a reversible caspase-3 inhibitor, in the rat malonate model of Huntington's disease. Br J Pharmacol 141:689-697.
301. 1 receptors in the rat central nervous system. Neuroscience 83:393-411.
302. Tsou K, Nogueron MI, Muthian S, Sañudo-Peña M, Hillard CJ, Deutsch DG, Walker JM (1998b) Fatty acid amide hydrolase is located preferentially in large neurons in the rat central nervous system as revealed by immunohistochemistry. Neurosci Lett 254:137-140.
303. Turmaine M, Raza A, Mahal A, Mangiarini L, Bates GP, Davies SW (2000) Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. Proc Natl Acad Sci USA 97:8093-8097.
304. Tzavara ET, Li DL, Moutsimilli L, Bisogno T, Di Marzo V, Phebus LA, Nomikos GG, Giros B (2006) Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia- related hyperactivity: Therapeutic implications. Biol Psychiatry 59:508-515.
305. Uchigashima M, Narushima M, Fukaya M, Katona I, Kano M, Watanabe M (2007) Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum. J Neurosci 27:3663-3676.
306. van der Stelt M, Di Marzo V (2003) The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: Implications for neurological and psychiatric disorders. Eur J Pharmacol 480:133-150.
307. van der Stelt M, Di Marzo V (2005) Cannabinoid receptors and their role in neuroprotection. Neuromol Med 7:37-50.
308. van der Stelt M, Veldhuis WB, Maccarrone M, Bar PR, Nicolay K, Veldink GA, Di Marzo V, Vliegenthart JF (2002) Acute neuronal injury, excitotoxicity, and the endocannabinoid system. Mol Neurobiol 26:317-346.
309. van der Stelt M, Fox SH, Hill M, Crossman AR, Petrosino S, Di Marzo V, Brotchie JM (2005) A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. FASEB J 19:1140-1142.
310. Vaney C, Heinzel-Gutenbrunner M, Jobin P, Tschopp F, Gattlen B, Hagen U, Schnelle M, Reif M (2004) Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: A randomized, double-blind, placebocontrolled, crossover study. Mult Scler 10:417-424.
311. 2 receptors. Science 310:329-332.
312. 3H]- GABA uptake in the rat globus pallidus. Exp Neurol 194:284-287.
313. Wade DT, Makela P, Robson P, House H, Bateman C (2004) Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Soler 10:434-441.
314. Walker FO (2007) Huntington's disease. Lancet 369:218-228.
315. Wallmichrath I, Szabo B (2002a) Analysis of the effect of cannabinoids on GABAergic neurotransmission in the substantia nigra pars reticulata. Naunyn Schmiedebergs Arch Pharmacol 365:326-334.
316. Wallmichrath I, Szabo B (2002b) Cannabinoids inhibit striatonigral GABAergic neurotransmission in the mouse. Neuroscience 113:671-682.
317. Walter L, Stella N (2004) Cannabinoids and neuroinflammation. Br J Pharmacol 141:775-785.
318. Wang W, Duan W, Igarashi S, Morita H, Nakamura M, Ross CA (2005) Compounds blocking mutant huntingtin toxicity identified using a Huntington's disease neuronal cell model. Neurobiol Dis 20:500-508.
319. Wang Z, Kai L, Day M, Ronesi J, Yin HH, Ding J, Tkatch T, Lovinger DM, Surmeier DJ (2006) Dopaminergic control of corticostriatal long-term synaptic depression in medium spiny neurons is mediated by cholinergic interneurons. Neuron 50:443-452.
320. Watanabe K, Kimura M (1998) Dopamine receptor-mediated mechanisms involved in the expression of learned activity of primate striatal neurons. J Neurophysiol 79:2568-2580.
321. Westlake TM, Howlett AC, Bonner TI, Matsuda LA, Herkenham M (1994) Cannabinoid receptor binding and messenger RNA expression in human brain: An in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains. Neuroscience 63:637-652.
322. Whitton PS (2007) Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol 150:963-976.
323. 9-Tetrahydrocannabinol and anandamide enhance the ability of muscimol to induce catalepsy in the globus pallidus of rats. Eur J Pharmacol 250:205-208.
324. 2 receptors and LTD: yes, but not where you thought they were. Neuron 50:347-348.
325. Wilson CJ, Kawaguchi Y (1996) The origins of two-state spontaneous membrane potential fluctuations of neostriatal spiny neurons. J Neurosci 16:2397-2410.
326. Wood-Kaczmar A, Gandhi S, Wood NW (2006) Understanding the molecular causes of Parkinson's disease. Trends Mol Med 12:521-528.
327. Wu SS, Frucht SJ (2005) Treatment of Parkinson's disease: What's on the horizon? CNS Drugs 19:723-743.
328. Yanovsky Y, Mades S, Misgeld U (2003) Retrograde signaling changes the venue of postsynaptic inhibition in rat substantia nigra. Neuroscience 122:317-328.
329. Yin HH, Knowlton BJ (2006) The role of the basal ganglia in habit formation. Nat Rev Neurosci 7:464-476.
330. 2 receptor-mediated inhibition of glutamate release by retrograde endocannabinoid signaling. Proc Natl Acad Sci USA 103:8251-8256.
331. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A (2003) Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomised placebo-controlled trial. Lancet 362:1517-1526.
332. Zajicek JP, Sanders HP, Wright DE, Vickery PJ, Ingram WM, Reilly SM, Nunn AJ, Teare LJ, Fox PJ, Thompson AJ (2005) Cannabinoids in multiple sclerosis (CAMS) study: Safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 76:1664-1669.
333. 1 receptor mRNA expression in 6-hydroxydopamine- lesioned rats. Neurosci Lett 276:71-74.
334. 1 receptor knockout mice. Proc Natl Acad Sci USA 96:5780-5785.